Cerebrolysin half-life & pharmacokinetics

Reported half-life

Variable across the multi-component preparation. Smaller peptide and amino acid components have plasma half-lives of minutes to hours; the integrated pharmacodynamic effect of intravenous administration persists for days through downstream effects on neurotrophin expression, neuroinflammation, and synaptic protein synthesis. The licensed clinical protocol uses daily intravenous infusion for 10-20 day treatment courses.

The half-life and pharmacokinetic profile of Cerebrolysin reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Intravenous infusion (standard licensed route; 5-50 mL daily dilution)
• Intramuscular injection (alternative licensed route, smaller doses)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Multi-component porcine brain-derived peptide and amino-acid preparation; neurotrophic and neuroprotective compound preparation registered as prescription medicine in 50+ countries (not UK).

Mechanism context

Half-life interpretation depends on the underlying mechanism. Cerebrolysin acts as follows:

Cerebrolysin is a complex multi-component preparation produced by Ever Pharma (Austria) through controlled enzymatic hydrolysis of lipid-free, standardised young porcine brain tissue. The final product is a sterile aqueous solution containing approximately 25% peptides of molecular weight below 10 kDa (including small biologically active peptides, neurotrophic-factor fragments, and peptide hormone fragments) and approximately 75% free amino acids. The compositional standardisation is achieved through controlled hydrolysis parameters and quality-control testing, but the preparation is fundamentally a complex mixture rather than a single defined peptide molecule — a critical mechanistic distinction from the other research peptides on this site.

See the full Cerebrolysin research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.